Project Grant R01HL182092
Award Date 7/22/26
Completion Date 3/31/31
Dollars Obligated $730K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $1,574,578 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel targeted modified mRNA delivery strategies for donation after circulatory death (DCD) heart transplantation. The research addresses primary graft dysfunction (PGD), an ischemia-reperfusion injury occurring in approximately 35 percent of heart transplants and driven by hyper-inflammatory responses involving...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $787,297 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 4, 2026. The award funds research into vascular dysfunction and lung allograft health, specifically investigating the mechanisms of primary graft dysfunction (PGD)—an ischemia-reperfusion injury that occurs in approximately 35 percent of lung transplants. The research examines how inflammasome-mediated pyroptosis and endothelial...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University $760,476 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a low-field magnetic resonance imaging guided robotic catheter system for ventricular tachycardia ablation. The project addresses recurrence rates as high as 37% in ventricular tachycardia (VT) ablation procedures, particularly in patients with extensive structural or non-ischemic heart disease. The system...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $236,250 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026, as a Project Grant (R21HL184279). The award funds secondary analysis of right heart catheterization data within the PVDOMICS cohort to phenotype right ventricular dysfunction across the pulmonary hypertension spectrum. The research will quantify right ventricular function including contractility, afterload, diastolic...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $249,000 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize genetic variants associated with doxorubicin-induced cardiotoxicity using induced pluripotent stem cell-derived cardiomyocytes. The award funds research to identify genetic determinants of doxorubicin-induced cardiotoxicity and enable precise risk stratification and cardioprotection. The principal investigator...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $249,000 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support post-transcriptional mechanisms of direct cardiac reprogramming. The project investigates how post-transcriptional regulation, including mRNA modification and translation, controls the conversion of cardiac fibroblasts into induced cardiomyocyte-like cells—a therapeutic approach to replace heart tissue lost to...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Ohio State University $772,931 on July 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate membrane-repairing long noncoding RNA MASIR as a therapeutic for ischemic heart injury. The award funds research into a sarcolemma-enriched long noncoding RNA termed MASIR (MG53-associated sarcolemma injury repair lncRNA) that promotes endocytosis and exocytosis to enhance cardiac...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University $109,076 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop improved cardiovascular risk prediction models using advanced computational methods applied to cardiac CT imaging. The research applies deep learning to detect small, low-density calcifications on coronary artery calcium score exams that are predictive of early-stage atherosclerosis and near-term...
- The National Heart, Lung, and Blood Institute (NHLBI) within the National Institutes of Health awarded The Ohio State University $121,658 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how inflamed adipose tissue modulates vascular inflammation through adipocyte-derived extracellular vesicles. The funded research decodes the role of adipocyte-derived extracellular vesicle cargo in promoting cardiovascular disease risk in obese populations. The...